Thomas Pabst at University Hospital Bern - Research Interests, Publications & Academic Profile

Thomas Pabst

University Name

Switzerland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Bangladeshi students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

60%

Pharmacotherapy

90%

Hematology

80%

Multiple Myeloma

80%

Cancer Therapy

70%

Stem Cell Transplantation

60%

Targeted Therapy

50%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles21

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Article Link

Year:

2024

Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia

Article Link

Year:

2024

Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma

Article Link

Year:

2024

Safety and Efficacy of High-Dose Chemotherapy with TreoMel 200 vs. TreoMel 140 in Acute Myeloid Leukemia Patients Undergoing Autologous Stem Cell Transplantation

Article Link

Year:

2024

Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery

Article Link

Year:

2024

Boosting CAR T cells against lymphomas

Article Link

Year:

2024

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT

Article Link

Year:

2024

A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications

Article Link

Year:

2024

Determinants of Interpatient Variability in Treosulfan Pharmacokinetics in AML Patients Undergoing Autologous Stem Cell Transplantation

Article Link

Year:

2024

True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations—Brief Report

Article Link

Year:

2024

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia

Article Link

Year:

2023

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

Article Link

Year:

2023

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma

Article Link

Year:

2023

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma

Article Link

Year:

2023

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

Article Link

Year:

2023

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma

Article Link

Year:

2023

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma

Article Link

Year:

2023

Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT

Article Link

Year:

2023

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Article Link

Year:

2023

Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Article Link

Year:

2022

Collaborators7

Michael Daskalakis

Assistant Professor, Head of Cellular Therapy Division, Director of autologous Stem Cell Program Inselspital

Inselspital Universitätsspital Bern

SWITZERLAND

Michael Nagler

SWITZERLAND

Patrick Hayden

Trinity College Dublin School of Medicine

IRELAND

Katja Seipel

University Hospital of Bern

SWITZERLAND

Henning Nilius

University of Bern

SWITZERLAND

Jaime Sanz

Profesor asociado asistencial

Universidad Católica de Valencia Facultad de Medicina

SPAIN

Ekaterina Rebmann

SWITZERLAND

How do Bangladeshi students reach out?

Meet Kite AI

Thomas Pabst

How do Bangladeshi students reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles21

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia

Rising Prevalence of Low-Frequency <i>PPM1D</i> Gene Mutations after Second HDCT in Multiple Myeloma

Safety and Efficacy of High-Dose Chemotherapy with TreoMel 200 vs. TreoMel 140 in Acute Myeloid Leukemia Patients Undergoing Autologous Stem Cell Transplantation

Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery

Boosting CAR T cells against lymphomas

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT

A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications

Determinants of Interpatient Variability in Treosulfan Pharmacokinetics in AML Patients Undergoing Autologous Stem Cell Transplantation

True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations—Brief Report

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma

Effect of MAPK activation via mutations in <i>NRAS</i>, <i>KRAS</i> and <i>BRAF</i> on clinical outcome in newly diagnosed multiple myeloma

Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients

Collaborators7

Michael Daskalakis

Michael Nagler

Patrick Hayden

Katja Seipel

Henning Nilius

Jaime Sanz

Ekaterina Rebmann

How do Bangladeshi students reach out?